Skip to main content

Traws Pharma, Inc.

TRAW
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001130598

No open-market purchases or sales by Traws Pharma, Inc. insiders were filed in the last 90 days; 34 institutions reported holding it in 13F filings for Q2 2026, worth $5.19M in total; no superinvestor holds it.

Key figures

Insider buysOpen market, last 90 days
0
Insider sellsOpen market, last 90 days
0
13F holdersQ2 2026, +6 vs. previous quarter
34
13F valueReported value at the end of Q2 2026
$5.19M
Superinvestors holdingAt the end of Q2 2026
0

Price chart

Superinvestors holding TRAW, Q2 2026

Go to the superinvestors tab

No superinvestor reported holding TRAW at the end of Q2 2026.

Latest insider trades

Open-market purchases and sales by Traws Pharma, Inc. insiders from Form 4, newest first.

See all insider trades
Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Apr 28, 2026 (view filing)9:41 PM ETApr 1612 daysLateOrbiMed Advisors LLC and 1 other10% OwnerPPurchase+597.7K$1.67+$998.2K+98.7%1.20M after
Apr 28, 2026 (view filing)9:41 PM ETApr 1612 daysLateOrbiMed Advisors LLC and 1 other10% OwnerPPurchase+2.99M–––1.79M afterDerivative3 lots
Jan 27, 2025 (view filing)7:03 PM ETDec 29, 202429 daysLateOrbiMed Advisors LLC and 1 other10% OwnerPPurchase+192.7K–––96.3K afterDerivative2 lotsDuplicate filing
Jan 27, 2025 (view filing)Dec 29, 202429 daysLateCautreels WernerChief Executive OfficerPPurchase+192.7K–––96.3K afterDerivative2 lotsDuplicate filing
Jan 27, 2025 (view filing)Dec 29, 202429 daysLateTpav, LLC10% OwnerPPurchase+192.7K–––96.3K afterDerivative2 lotsDuplicate filing
Jan 27, 2025 (view filing)Dec 29, 202429 daysLateSavchuk NikolayChief Operating OfficerPPurchase+192.7K–––96.3K afterDerivative2 lots
Jan 31, 2022 (view filing)Jan 283 daysOler Abraham N.SVP Corp Dev & Gen CounselPPurchase+1.50K$1.67+$2.50K+6.5%24.5K after
Jan 24, 2022 (view filing)Jan 213 daysOler Abraham N.SVP Corp Dev & Gen CounselPPurchase+1.50K$2.02+$3.03K+7.0%23.0K after
Jan 18, 2022 (view filing)Jan 144 daysOler Abraham N.SVP CORP DEV & GEN COUNSELPPurchase+1.50K$2.20+$3.30K+7.5%21.5K after
Jan 10, 2022 (view filing)Jan 73 daysOler Abraham N.SVP Corp Dev & Gen CounselPPurchase+1.50K$2.39+$3.58K+8.1%20.0K after

Top 10 13F holders, Q2 2026

The largest institutional positions in Traws Pharma, Inc. at the end of Q2 2026; share changes are against Q1 2026.

See all 34 holders
Institutions holding TRAW in Q2 2026
InstitutionSharesValue% of portfolioChange in sharesAction
OrbiMed Advisors LLC1,203,260$1.01M0.02%+597,729+98.7%Added
Ally Bridge Group (NY) LLC786,236$663.0K0.85%+786,236New
Adage Capital Partners GP, L.L.C.730,000$615.6K0.00%00.0%Unchanged
ADAR1 Capital Management, LLC597,729$504.1K0.02%+443,631+287.9%Added
Lynx1 Capital Management LP559,470$471.8K0.05%+544,392+3,610.5%Added
Ikarian Capital, LLC478,142$403.2K0.07%−200,000−29.5%Reduced
Sphera Funds Management Ltd.398,486$336.0K0.05%+398,486New
Vanguard Capital Management LLC330,049$278.2K0.00%+274,856+498.0%Added
Jane Street Group, LLC216,006$182.2K0.00%+194,765+916.9%Added
Alyeska Investment Group, L.P.164,376$138.6K0.00%+164,376New